1,341 reports of this reaction
1.8% of all TORSEMIDE reports
#14 most reported adverse reaction
CARDIAC FAILURE is the #14 most commonly reported adverse reaction for TORSEMIDE, manufactured by Sarfez Pharmaceuticals Inc. There are 1,341 FDA adverse event reports linking TORSEMIDE to CARDIAC FAILURE. This represents approximately 1.8% of all 74,224 adverse event reports for this drug.
TORSEMIDE has an overall safety score of 85 out of 100. Patients taking TORSEMIDE who experience cardiac failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CARDIAC FAILURE is a less commonly reported adverse event for TORSEMIDE, but still significant enough to appear in the safety profile.
In addition to cardiac failure, the following adverse reactions have been reported for TORSEMIDE:
The following drugs have also been linked to cardiac failure in FDA adverse event reports:
CARDIAC FAILURE has been reported as an adverse event in 1,341 FDA reports for TORSEMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CARDIAC FAILURE accounts for approximately 1.8% of all adverse event reports for TORSEMIDE, making it a notable side effect.
If you experience cardiac failure while taking TORSEMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.